[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-366566-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-366566-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-prognostic-value-of-cip2a-and-its-association-with-cd31-e-cadherin-and-pampk-in-lung-cancer","The Prognostic Value of CIP2A and Its Association with CD31, E-Cadherin, and pAMPK in Lung Cancer","","Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein implicated in tumor progression through multiple signaling pathways, yet its prognostic relevance in lung cancer remained insufficiently defined. Tumor samples from 53 patients undergoing curative surgical resection without prior chemotherapy or radiotherapy were analyzed. Immunohistochemistry and H-score quantification evaluated CIP2A and related marker expression, followed by survival stratification and correlation with clinicopathological and molecular indicators. High CIP2A expression predicted significantly poorer overall survival, correlating positively with CD31, E-cadherin, and pAMPK-associated signaling while showing a negative relationship with phosphorylated AMPK, suggesting roles in angiogenesis maintenance of epithelial traits and metabolic suppression.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-prognostic-value-of-cip2a-and-its-association-with-cd31-e-cadherin-and-pampk-in-lung-cancer/366566/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-prognostic-value-of-cip2a-and-its-association-with-cd31-e-cadherin-and-pampk-in-lung-cancer/366566.png","ImageObject",300,407,{"name":42,"@type":43},"4398046744996","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What question does the study address about CIP2A in lung cancer?","Question",{"text":63,"@type":64},"The study evaluates whether CIP2A has prognostic significance in lung cancer and how its expression is associated with CD31, E-cadherin, and pAMPK-related signaling markers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were CIP2A and related proteins measured in the patient cohort?",{"text":68,"@type":64},"CIP2A and related proteins were assessed using immunohistochemical staining, with H-score quantification to represent expression levels.",{"name":70,"@type":61,"acceptedAnswer":71},"What is the main survival finding related to CIP2A expression?",{"text":72,"@type":64},"Patients with high CIP2A expression showed significantly poorer survival based on Kaplan–Meier analysis and log-rank testing.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},366566,1790217367,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":11,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":133,"file_id":134,"file_url":135,"file_type":136,"file_size":137,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":138,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144},4398046744996,"Article  \nThe Prognostic Value of CIP2A and Its Association with CD31, E-Cadherin, and pAMPK in Lung Cancer  \nPeng Yu Lee 1,†, Ching-Yu Shih 2,†, Chiao-Yin Cheng 1, Hua Ho 1, Yen-Lin Chen 3, * and Chih-Jung Chang 1,4, *  \nAcademic Editor: Regina M. Day  \nReceived: 29 June 2025  \nRevised: 10 August 2025  \nAccepted: 27 August 2025  \nPublished: 28 August 2025  \nCitation: Lee, P.Y.; Shih, C.-Y.; Cheng, C.-Y.; Ho, H.; Chen, Y.-L.; Chang, C.-J. The Prognostic Value ofCIP2A andIts Association with CD31, E-Cadherin, and pAMPKin Lung Cancer. Int. J. Mol. Sci. 2025, 26, 8362. [https://](https://)[ ](https://)[doi.org/10.3390/ijms26178362](doi.org/10.3390/ijms26178362)  \n[Copyright:](Copyright:) © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Department of Emergency Medicine, Far Eastern Memorial Hospital, New Taipei 220, Taiwan; [femh97681@femh.org.tw](femh97681@femh.org.tw) (P.Y.L.); [femhr9969@femh.org.tw](femhr9969@femh.org.tw) (C.-Y.C.); [femh97657@femh.org.tw](femh97657@femh.org.tw) (H.H.)  \n2 Center for Precision Medicine and Genomics, Tri-Service General Hospital, National Defense Medical University, Taipei 114, Taiwan; [c588011124@tsghms.ndmctsgh.edu.tw](c588011124@tsghms.ndmctsgh.edu.tw)  \n3 Department of Pathology, Center for Precision Medicine and Genomics, Tri-Service General Hospital, National Defense Medical University, Taipei 114, Taiwan  \n4 Graduate Institute of Medicine, Yuan Ze University, Taoyuan City 320, Taiwan  \n* [Correspondence: yenlinchen12742@mail.ndmctsgh.edu.tw](Correspondence: yenlinchen12742@mail.ndmctsgh.edu.tw) (Y.-L.C.); [femh88558@femh.org.tw](femh88558@femh.org.tw) (C.-J.C.);  \nTel.: +886-2-87923311 (Y.-L.C.); +886-2-77281125 (C.-J.C.)† These authors contributed equally to this work.  \nAbstract  \nCancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein promoting tumor progression via multiple pathways. Its prognostic significance in lung cancer remains unclear. We analyzed tumor samples from 53 patients with lung cancer undergoing curative surgical resection without prior chemotherapy or radiotherapy. Immunohistochemical staining and H-score quantification were performed to assess CIP2A and related protein expression. Patients were stratified based on CIP2A expression (cutoff value = 218.33) . Kaplan–Meier survival analysis produced curves and log-rank tests. Correlations with clinicopathological and molecular markers were assessed. High CIP2A expression was significantly associated with poorer survival (log-rank, p = 0.0051) . Pearson correlation analysis revealed that CIP2A expression was positively correlated with clusters of differentiation 31 (r = 0.420, p = 0.002), epithelial cadherin (r = 0.372, p = 0.006), and phosphorylated protein kinase B (r = 0.332, p = 0.015), and negatively correlated with phosphorylated AMPactivated protein kinase (r = −0.474, p \u003C 0.001), suggesting potential roles for CIP2A in promoting angiogenesis, sustaining epithelial traits, and suppressing metabolic regulation via AMPK signaling. CIP2A is a significant prognostic biomarker in lung cancer, contributing to tumor progression through modulation of angiogenesis and metabolic pathways. Exploration of its therapeutic potential and underlying mechanisms is warranted.  \nKeywords: CIP2A; lung cancer; CD31; AMPK; AKT  \n1. Introduction  \nLung cancer is one of the most common and deadliest malignancies worldwide. In 2020, it accounted for over 2.2 million new cases and 1.8 million deaths globally, representing approximately 18% of all cancer-related deaths [1,2] . Although countries like the United States have seen declines in lung cancer mortality due to anti-smoking campaigns and early screening, the global burden remains substantial","cbCaif5QJly2ON2T","https://ap.wps.com/l/cbCaif5QJly2ON2T","pdf",1458210,14,"English","# Abstract\n# Keywords\n# 1. Introduction","[{\"question\":\"What question does the study address about CIP2A in lung cancer?\",\"answer\":\"The study evaluates whether CIP2A has prognostic significance in lung cancer and how its expression is associated with CD31, E-cadherin, and pAMPK-related signaling markers.\"},{\"question\":\"How were CIP2A and related proteins measured in the patient cohort?\",\"answer\":\"CIP2A and related proteins were assessed using immunohistochemical staining, with H-score quantification to represent expression levels.\"},{\"question\":\"What is the main survival finding related to CIP2A expression?\",\"answer\":\"Patients with high CIP2A expression showed significantly poorer survival based on Kaplan–Meier analysis and log-rank testing.\"}]","The Prognostic Value of CIP2A and Its Association with CD31, E-Cadherin, and pAMPK in Lung Cancer | PDF",1790166096,35]